Dr. Larson on Immunotherapy for Colorectal Cancer

Tim G. Larson, MD
Published: Monday, Sep 25, 2017



Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Immunotherapies have seen success in patients with microsatellite instability-high (MSI-H) CRC even though this only includes a small percentage of patients, states Larson. Patients with microsatellite stable (MSS) CRC have not seen the same results but this is under current investigation since they make up 95% of the patient population.

Unique combinations or molecules might show some signs of progress for these patients, explains Larson.
 


Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Immunotherapies have seen success in patients with microsatellite instability-high (MSI-H) CRC even though this only includes a small percentage of patients, states Larson. Patients with microsatellite stable (MSS) CRC have not seen the same results but this is under current investigation since they make up 95% of the patient population.

Unique combinations or molecules might show some signs of progress for these patients, explains Larson.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x